The first of a series of new compounds at Psilera is confirmed as non-hallucinogenic at greater than ten times the dosing of N,N-dimethyltryptamine (DMT) with further biological and behavioral assessments in progress TAMPA, Fla., Dec. 7, 2021 /PRNewswire-PRWeb/ — Psilera Inc. (“Psilera”), a Florida-based biotechnology company developing non-hallucinogenic derivatives of psychedelic compounds and…


Previous articleEditor’s Choice Award 2021-Best Study on Psychedelics and Nature
Next articleMindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System